Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em

NCT06475989 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT06475989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06475989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Recruiting
Start date
December 27, 2024
Completion date
September 30, 2030
Enrollment
264 (estimated)
Sites
307

Conditions

As the registry lists them; a condition with its own page is linked.

refractory differentiated thyroid gland carcinoma